Mohamed Farhan Nasser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Farhan Nasser has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Jabri
Heart and Vascular Center, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA
3 shared publications- Ahmad Jabri
William Beaumont University Hospital
2 shared publications Saima Karim
Heart and Vascular Center, Metrohealth Campus of Case-Western Reserve University, Cleveland, Ohio, USA
2 shared publicationsAdil F. Vural
Department of Rheumatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
1 shared publicationAdnan Yusaf
Heart and Vascular Center, Metrohealth Campus of Case-Western Reserve University, Cleveland, Ohio, USA
1 shared publication- Ahmad Al-Abdouh
Department of Medicine, Saint Agnes Hospital, Baltimore, MD, United States of America
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Outcomes of Mechanical Thrombectomy in Older Patients With Pulmonary Embolism
- 27 October 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Open AccessOutcomes of Mechanical Thrombectomy in Older Patients With Pulmonary Embolism
- Open Access
- 11 December 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (5) , 106235
Giant Cell Arteritis Causing Isolated Pulmonary Artery Aneurysm
- 11 December 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (5) , 106235
Open AccessGiant Cell Arteritis Causing Isolated Pulmonary Artery Aneurysm
- Open Access
- 5 November 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (41)
Darting Waves and Diagnostic Twists
- 5 November 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (41)
Open AccessDarting Waves and Diagnostic Twists
- 25 April 2022
- Published by SAGE Publications in Vascular Medicine
- Vol. 27 (3) , 296-301
Manifestations of circulatory assist devices in noninvasive arterial duplex evaluation: A pictorial review
Spectral Doppler and plethysmographic waveforms vary significantly in the presence of circulatory assist devices. Understanding the effect these devices have on the waveforms and flow characteristics is necessary for the appropriate interpretation of duplex ultrasound and other noninvasive vascular studies. We review the different arterial waveforms that can be seen with circulatory assist devices.
- 25 April 2022
- Published by SAGE Publications in Vascular Medicine
- Vol. 27 (3) , 296-301
Manifestations of circulatory assist devices in noninvasive arterial duplex evaluation: A pictorial review
Spectral Doppler and plethysmographic waveforms vary significantly in the presence of circulatory assist devices. Understanding the effect these devices have on the waveforms and flow characteristics is necessary for the appropriate interpretation of duplex ultrasound and other noninvasive vascular studies. We review the different arterial waveforms that can be seen with circulatory assist devices.
- 1 December 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 134 (12) , 1465-1475
Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review
- 1 December 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 134 (12) , 1465-1475
Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review
- Open Access
- 1 September 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (11) , 1370-1372
The Spiked Helmet Sign
- 1 September 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (11) , 1370-1372
Open AccessThe Spiked Helmet Sign
- 19 August 2021
- Published by Springer Nature in Current Cardiology Reports
- Vol. 23 (10) , 1-12
Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and Guidelines
Purpose of Review Pregnancy-associated myocardial infarction is a principal cause of cardiovascular disease with a steadily rising incidence of 4.98 AMI events/100,000 deliveries over the last four decades in the USA. It is also linked with significant maternal and fetal morbidity and mortality, with maternal case fatality rate ranging from 5.1 to 37%. The management of acute myocardial infarction can be challenging in pregnant patients since treatment modalities and medication use are limited by their safety during pregnancy. Recent Findings Limited guidelines exist regarding the management of pregnancy-associated myocardial infarction. Routinely used medications in myocardial infarction including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and statin therapy are contraindicated during pregnancy. Aspirin use is considered safe in pregnant women, but dual antiplatelet therapy and therapeutic anticoagulation can be associated with increased risk of maternal and fetal complications, and should only be used after a comprehensive benefit-to-risk assessment. The standard approach to revascularization requires additional caution in pregnant women. Percutaneous coronary intervention is generally considered safe but can be associated with high failure rates and poor outcomes depending on the etiology. Fibrinolytic therapy may have significant sequelae in pregnant patients, and hemodynamic management during surgery is complex and adds risk during pregnancy. Summary Understanding the risks and benefits of the different treatment modalities available and their utility depending on the underlying etiology, encompassed with a multidisciplinary team approach, is vital to improve outcomes and minimize maternal and fetal complications.
- 19 August 2021
- Published by Springer Nature in Current Cardiology Reports
- Vol. 23 (10) , 1-12
Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and Guidelines
Purpose of Review Pregnancy-associated myocardial infarction is a principal cause of cardiovascular disease with a steadily rising incidence of 4.98 AMI events/100,000 deliveries over the last four decades in the USA. It is also linked with significant maternal and fetal morbidity and mortality, with maternal case fatality rate ranging from 5.1 to 37%. The management of acute myocardial infarction can be challenging in pregnant patients since treatment modalities and medication use are limited by their safety during pregnancy. Recent Findings Limited guidelines exist regarding the management of pregnancy-associated myocardial infarction. Routinely used medications in myocardial infarction including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and statin therapy are contraindicated during pregnancy. Aspirin use is considered safe in pregnant women, but dual antiplatelet therapy and therapeutic anticoagulation can be associated with increased risk of maternal and fetal complications, and should only be used after a comprehensive benefit-to-risk assessment. The standard approach to revascularization requires additional caution in pregnant women. Percutaneous coronary intervention is generally considered safe but can be associated with high failure rates and poor outcomes depending on the etiology. Fibrinolytic therapy may have significant sequelae in pregnant patients, and hemodynamic management during surgery is complex and adds risk during pregnancy. Summary Understanding the risks and benefits of the different treatment modalities available and their utility depending on the underlying etiology, encompassed with a multidisciplinary team approach, is vital to improve outcomes and minimize maternal and fetal complications.
- Open Access
- 1 June 2021
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 7 (6) , 354-356
The importance of use of appropriate anticoagulant in atrial fibrillation after gastric bypass surgery
- 1 June 2021
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 7 (6) , 354-356
Open AccessThe importance of use of appropriate anticoagulant in atrial fibrillation after gastric bypass surgery